Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

UGN-201 for the Treatment of Bladder Cancer in Patients Undergoing Radical Cystectomy

Trial Status: closed to accrual

This phase I trial tests the safety of UGN-201 in treating patients with bladder cancer undergoing radical cystectomy. UGN-201 is a formulation of the drug imiquimod that has been developed to be given directly into the bladder and may stimulate the immune system. Giving UGN-201 may improve immune response in patients with bladder cancer undergoing radical cystectomy.